Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could the gut hold clues to Parkinson's disease?

NCT ID NCT05787756

Knowledge-focused Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers at the University of Aberdeen are investigating whether gut bacteria differ in people with Parkinson's disease, especially those with constipation. They will collect stool samples from 30 participants: newly diagnosed Parkinson's patients who have not yet started medication, and healthy household members as controls. The samples will be analyzed for microbial DNA and short-chain fatty acids to see if gut health changes relate to Parkinson's. This pilot study aims to uncover connections that could guide future research into gut-based approaches.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the link is clear, this could point toward gut-based therapies or earlier detection for Parkinson's disease.
What could go wrong
This is a small pilot study with 30 participants, so findings may not apply broadly. It only observes, not tests a treatment, so it cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Jan 2023

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Parkinson disease group: potential participants will be invited into the study if they have recently been diagnosed with Parkinson's disease and have not yet started medication for the condition Control group: spouses or other household contacts will be invited to the study

Ages

18 to 110 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants with Parkinson's disease 2. Community-dwelling patients with newly diagnosed PD who have not yet started medication for Parkinson's disease. Control Participants 1\. Healthy (non-Parkinsonian) members of the participants household will be invited to act as controls. Exclusion Criteria: 1. Use of oral or intravenous antibiotics in the last 8 weeks. 2. Active gastrointestinal disease, not including constipation or irritable bowel syndrome without other symptoms. 3. Current use of medications which cause/worsen constipation e.g., opioids, tramadol, gabapentin, pregabalin. 4. Potential controls will be excluded if they report prodromal symptoms of PD, such as anosmia or rapid eye movement (REM) sleep disorder or display parkinsonian signs on examination. 5. Inability to give informed consent at any stage of the study e.g., because of dementia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Human Nutrition Unit, Rowett Institute, University of Aberdeen

    Aberdeen, Aberdeen City, AB25 2ZD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.